Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, G., Cramer, P., Demirkan, F., Silva, R. Santucci, Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M.-S., Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., Karlsson, C., Hallek, M., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A., Chanan-Khan, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484712/
https://www.ncbi.nlm.nih.gov/pubmed/30315239
http://dx.doi.org/10.1038/s41375-018-0276-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484712/
https://www.ncbi.nlm.nih.gov/pubmed/30315239
http://dx.doi.org/10.1038/s41375-018-0276-9

Ejemplares similares